CytoTools AG announced that it has the preliminary results of the test series on the efficacy of the active ingredient DPOCL on influenza viruses. As expected, the clearly virucidal effect of DPOCL was also demonstrated with regard to this virus strain. This was already demonstrated on the COVID-19-causing Sars-Cov-2 pathogen in November. In the cell culture experiments now completed, the efficacy of DPOCL on influenza viruses was investigated in combination with human cells. As in the tests with Sars-CoV-2, a dose-dependent effect was observed. At the highest dosage, an efficiency of over 90 percent was observed. The company has furthermore received the final results report on the Sars-CoV-2 virus. This confirms the efficacy of DPOCL on Sars-CoV-2 viruses with an inhibition of over 95%. The new results make the targeted therapeutic approach, in which DPOCL is taken as an inhalation component with physiological saline via commercially available inhalers several times per day, much more attractive to potential project partners. In addition to its efficacy against the Sars-CoV-2 virus, the compound is thus gaining importance beyond the COVID-19 pandemic.